// App-Quantinova.ai

P210 : Long-Term Predictors of Relapse or Disability Progression in Patients with Multiple Sclerosis in the Transforms and Freedoms/Freedoms II Studies

Researchers

Presenter

  • Pavle Repovic

Principal Investigators

  • Aaron Boster

  • Davorka Tomic

  • Xiangyi Meng

  • Daniela Piani Meier

  • Frederik Barkhof

  • Till Sprenger

Medical Centers

  • 1Multiple Sclerosis Center, Swedish Neuroscience Institute Seattle WA United States

  • OhioHealth Neurological Physicians, Columbus, OH

  • Novartis AG, Basel, Switzerland

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • VU University Medical Center, Amsterdam, Netherlands

  • Institute of Healthcare Engineering, UCL, London, United Kingdom

  • University Hospital Basel, Basel, Switzerland

  • DKD HELIOS Klinik, Wiesbaden, Germany

Locations

  • United States

  • Switzerland

  • Netherlands

  • United Kingdom

  • Germany

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Dermatology

  • Genetic Disorder

Disease

  • Multiple Sclerosis

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Fingolimod

  • Interferon

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved